Indomethacin Capsules 25mg Generic Finished Western Medicine with GMP

Product Details
Customization: Available
Application: Internal Medicine
Usage Mode: For oral administration
Still deciding? Get samples of $ !
Request Sample

360° Virtual Tour

Diamond Member Since 2025

Suppliers with verified business licenses

Audited Supplier Audited Supplier

Audited by an independent third-party inspection agency

High Repeat Buyers Choice
More than 50% of buyers repeatedly choose the supplier
Years of Export Experience
The export experience of the supplier is more than 10 years
Exhibition Experience
The supplier had participated in offline trade shows, you can check the Audit Report for more information
Experienced Team
The supplier has 18 foreign trading staff(s) and 6 staff(s) with over 6 years of overseas trading experience
to see all verified strength labels (26)
  • Indomethacin Capsules 25mg Generic Finished Western Medicine with GMP
  • Indomethacin Capsules 25mg Generic Finished Western Medicine with GMP
  • Indomethacin Capsules 25mg Generic Finished Western Medicine with GMP
  • Indomethacin Capsules 25mg Generic Finished Western Medicine with GMP
  • Indomethacin Capsules 25mg Generic Finished Western Medicine with GMP
  • Indomethacin Capsules 25mg Generic Finished Western Medicine with GMP
Find Similar Products

Basic Info.

Model NO.
AMC11007-02
Suitable for
Elderly, Children, Adult
State
Solid
Shape
Capsules
Type
Biological Products
Pharmaceutical Technology
Chemical Synthesis
Standard Available
Bp, Cp
Function
Antipyretic Analgesics
Delivery Time
30~60 Days
OEM/ODM
Support
Transport Package
Box
Specification
25MG, 1000′S/BOTTLE
Trademark
Shinepharm
Origin
China
HS Code
3004909099
Production Capacity
1000000 Boxes/Month

Product Description

Product Description
Indomethacin Capsules 25mg Generic Finished Western Medicine with GMP

INDOMETHACIN CAPSULE 25mg

Indications:

The treatment of rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute musculoskeletal disorders and acute gout.

Contra-indications:

Active peptic ulcer or a history of recurrent gastro-intestinal lesions. Sensitivity to aspirin, indometacin or other non-steroidal anti-inflammatory agents.

Pregnancy or lactation.

Patients operating machinery.

Patients with epilepsy, parkinsonism, psychiatric disturbances or porphyria.

Children, since conditions for safe use have not been established.

Severe heart failure.

Adverse Effects:

Most adverse effects are dose related

Gastro-intestinal adverse effects are common and include anorexia, nausea (with or without vomiting) dyspepsia, abdominal pain and diarrhoea. Infrequently, ulceration of the upper GI tract, sometimes with perforation and haemorrhage, has occurred. Acute pancreatitis has been reported. Hepatic involvement is rare, though fatal cases of hepatitis and jaundice have been reported.

CNS effects are also common. Severe frontal headache may occur in 25 - 50% of patients who take the drug chronically. Dizziness, light-headedness, vertigo and mental confusion are also frequent. Depression and psychosis have also been reported but the incidence is less than 1%.

Haemopoietic reactions, including neutropenia, thrombocytopenia and, rarely, aplastic anaemia have been reported.

Hypersensitivity reactions, manifested as rashes, itching, urticaria or rarely acute asthma, may occur.

Oedema, hypertension, and cardiac failure, have been reported in association with NSAID treatment.

Drug Interactions:

1.Probenecid. The plasma concentration of Indometacin is increased.

2.Frusemide. The natriuretic and anti-hypersensitivity effects are antagonised by Indometacin.

3.Thiazide diuretics and beta-blocking agents. Indometacin reduces the anti-hypertensive effects of these compounds.

4.Antacids. The bioavailability of Indometacin may be reduced by concomitant antacid therapy.

5.Triamterene. Acute renal failure has been reported with concomitant Indometacin therapy.

Precautions & Warning:

Indometacin should be used with great care in elderly patients. Indometacin should be used with caution in patients with impaired renal function. Indometacin inhibits platelet aggregation and prolongs bleeding time. It should be used with caution therefore in patients with bleeding disorders, and concurrent administration of anti-coagulant agent may be hazardous because of increased risk of gastrointestinal bleeding.

Peptic ulcer has been reported in a small proportion of patients. If G.I. bleeding occurs, indometacin should be discontinued immediately. Indometacin may mask the signs and symptoms of infection. If clinical signs of hepatic disease develop, or if liver function tests become abnormal, indometacin should be withdrawn. Indometacin should be given with or immediately after food in order to lessen the incidence and severity of gastrointestinal side-effects.

Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.2, and GI and cardiovascular risks below).

Use in Pregnancy and Nursing Mothers:

Indometacin is contraindicated during pregnancy and lactation.

Treatment/antidote in The Event of Overdose:

Gastric lavage should be performed if ingestion is recent. Otherwise, supportive measures and observation.

Storage instructions:

Store below 25ºC. Protect from moisture. Keep out of reach of children.

Other Specification:

 

AMC11007-01 INDOMETHACIN CAPSULE 25MG,10*10/BOX
AMC11007-02 INDOMETHACIN CAPSULE 25MG,1000'S/BOTTLE
AMC11007-03 INDOMETHACIN CAPSULE 250MG,10'S*10/BOX
AMC11007-04 INDOMETHACIN CAPSULE 20MG,10'S*10/BOX

 

Indomethacin Capsules 25mg Generic Finished Western Medicine with GMPIndomethacin Capsules 25mg Generic Finished Western Medicine with GMP

Indomethacin Capsules 25mg Generic Finished Western Medicine with GMP

 

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier